These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 16979994)

  • 1. Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients.
    Liang MZ; Lu YP; Nan F; Li YP
    Transplant Proc; 2006 Sep; 38(7):2044-7. PubMed ID: 16979994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
    Jiao Z; Zhong JY; Zhang M; Shi XJ; Yu YQ; Lu WY
    Eur J Clin Pharmacol; 2007 Jan; 63(1):27-37. PubMed ID: 17093994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function.
    Wigger M; Armstrong VW; Shipkova M; Wacke R; Nizze H; Streit F; von Ahsen N; Muscheites J; Glasenapp S; Stolpe HJ; Oellerich M
    Ther Drug Monit; 2002 Jun; 24(3):438-43. PubMed ID: 12021639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT; Lamersdorf T; Shipkova M; Niedmann PD; Wiesel M; Zimmerhackl LB; Staskewitz A; Schütz E; Mehls O; Oellerich M; Armstrong VW; Tönshoff B
    Ther Drug Monit; 1999 Oct; 21(5):498-506. PubMed ID: 10519445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT; Shipkova M; Lamersdorf T; Niedmann PD; Wiesel M; Mandelbaum A; Zimmerhackl LB; Schütz E; Mehls O; Oellerich M; Armstrong VW; Tönshoff B
    J Am Soc Nephrol; 1998 Aug; 9(8):1511-20. PubMed ID: 9697675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.